Progyny (PGNY)
(Delayed Data from NSDQ)
$26.95 USD
+0.33 (1.24%)
Updated May 31, 2024 04:00 PM ET
After-Market: $26.97 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Progyny, Inc. [PGNY]
Reports for Purchase
Showing records 61 - 80 ( 103 total )
Company: Progyny, Inc.
Industry: Medical Services
2023 Life Sciences & MedTech Investor Forum: Key Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
PGNY Member Portal App Showing Sharp Sequential Monthly Increases Since Its Launch in Early December
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
2023 KBCM Life Sciences & MedTech Forum: Day 1 Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
1Q Setup Bodes Well for Beat & Raise Story on Large Client Wins and Healthy Pipeline; Remain Overweight
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Another Short Report Highlighting Tech Layoffs & Balance Sheet Questions
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Company: Progyny, Inc.
Industry: Medical Services
Healthcare IT: Recap from Large HC Industry Conference
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Progyny, Inc.
Industry: Medical Services
Expects 4Q22 and 2022 Revenue Guidance to Come in at or Near the High-End; Early Activity in 2023 with Prospective Clients Looks Very Encouraging
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department